In today’s briefing:
- Mahindra & Mahindra (MM IN) | Scorpio-N Fake Bookings
- Breaking Estimates Short Candidates: Kulicke & Soffa, Kronos, Marvell Tech, Montauk Renewables
- Vertex Pharmaceuticals (VRTX US): A High-Quality Deep Pocket Biotech Must-Have for Every Investor
- Taiwan Tech Weekly: Micron Earnings Miss Implies Margin Downside, Hon Hai Moving 30% Apple Business
- Delta Taiwan Vs. Thailand Monitor: Delta Thai Joining SET50, Could Open Up Rare Rel Valuation Level
- Micron Fiscal Q1: Short-Term Pain For Long-Term Gain
- Splunk Is A Rare Tech Growth Opportunity For 2023
Mahindra & Mahindra (MM IN) | Scorpio-N Fake Bookings
- One of our routine channels is suggesting the possibility of some of Mahindra & Mahindra (MM IN) ‘s Scorpio-N bookings being fake.
- This channel (an online auto forum) has been a trusted source of information followed by various industry veterans including the company’s chairman.
- While the rationalisation of fake bookings as a recent industry practice could solace some, the fallacy of the bookings narrative only gets stronger.
Breaking Estimates Short Candidates: Kulicke & Soffa, Kronos, Marvell Tech, Montauk Renewables
- This model finds companies facing recent sharp cuts in estimates. These shorts can have very disparate characteristics.
- The key judgement involves whether the negative revisions are temporary or if they are indications of ongoing weakness in the business.
- Breaking Estimates stocks often continue to decline after the cuts. This week we flag: Kulicke & Soffa, Kronos, Marvell Tech, Montauk Renewables
Vertex Pharmaceuticals (VRTX US): A High-Quality Deep Pocket Biotech Must-Have for Every Investor
- Vertex Pharmaceuticals (VRTX US), the global leader in cystic fibrosis treatment, has a broad and deep clinical pipeline across multiple modalities. Each of its clinical programs represents a multibillion-dollar opportunity.
- MRNA drug candidate for treating the remaining 5,000 CF patients who cannot benefit from existing therapies, is set to enter clinic. Drug candidate for acute pain is in late-stage trial.
- Regulatory submission for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia in U.S., EU and UK are expected to be completed by 1Q23.
Taiwan Tech Weekly: Micron Earnings Miss Implies Margin Downside, Hon Hai Moving 30% Apple Business
- Micron released its latest results, missing expectations and implying more near-term pain for the memory chip space.
- Hon Hai could shift 30% of its production for Apple outside of China according to an industry report.
- Intel delays German expansion citing cost inflation, seeking additional government subsidies.
Delta Taiwan Vs. Thailand Monitor: Delta Thai Joining SET50, Could Open Up Rare Rel Valuation Level
- Delta Thailand will be joining the Thailand SET50 Index, as was predicted by Brian Freitas here on Smartkarma.
- The “Illogical” valuation is back — Delta Taiwan trades as a smaller company despite being a substantially larger franchise.
- Opportunity — Index-Related buying of Delta Thailand could open up one of the most historically extreme relative valuations for Delta Taiwan.
Micron Fiscal Q1: Short-Term Pain For Long-Term Gain
- Micron Technology, Inc. reported fiscal Q1 2023 earnings and announced cost-cutting measures.
- Macroeconomic trends are still a drag, according to the company.
- The company also announced cost cutting measures for the next year’s fiscal year.
Splunk Is A Rare Tech Growth Opportunity For 2023
- Splunk is stronger with Q3 earnings and guidance. The company is shadowed by takeover talk.
- The company has a strong cloud market make it a buy. The firm is shadowing by takeover talks.
- The firm has been in the news for more than two years.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
